Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction is expected to close in the first quarter of 2022
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company expects strong organic growth in sales, EBITDA in 2022
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)